Korean J Urol.  1987 Jun;28(3):351-355.

Prophylactic Effectiveness of Intravesical Mitomycin C Instillation to Prevent Recurrence of Superficial Bladder Carcinoma after Transurethral Resection

• Kim DS
• Yoon DK

Abstract

Transurethral resection is the mainstay of curative treatment for superficial bladder cancer. Unfortunately, tumors recur in 40~70% of patients. Recently, we tried intravesical Mitomycin C chemotherapy after TUR to eliminate or decrease the frequency of recrrence. In this study, 22 patients with superficial bladder carcinoma received Mitomycin C intravesically at weekly intervals for eight weeks in dose of 40mg/40ml, starting about 48 hours after TUR. The results were compared to a group consists of 39 patients with superficial bladder cancer who received no further therapy after TUR. In the follow-up of 6 and 12 months, tumor recurrence was l3.6(3pts) and 18.2(4pts) percent respectively, in the Mitomycin C group, and 38.5(15pts, and 43.6(17 pts) per cent, respectively, in the control group. The frequency of recurrence in the Mitomycin C group was significantly less than that in the control group in the follow-up of both 6(P< 0.05) and 12 months(P< 0.05). Side effects of intravesical Mitomycin C therapy were negligibly minimal. Therefore, Mitomycin C intravesical chemotherapy after TUR is effective prophylactic treatment in reducing bladder tumor recurrence.

Keyword

recurrence; superficial bladder carcinoma; prophylacsis; intravesical chemotherapy; mitomycin c

MeSH Terms

Drug Therapy
Follow-Up Studies
Humans
Mitomycin*
Recurrence*
Urinary Bladder Neoplasms
Urinary Bladder*
Mitomycin